Nonalcoholic fatty liver disease can no longer be considered a benign entity, as the fat infiltration of the hepatic parenchyma is significantly associated with visceral adiposity, features of the metabolic risk (mainly increased risk for prediabetes and type 2 diabetes and anticipated cardiovascular disease). No matter what the mechanisms of the progression from nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) are, it seems that even fatty liver can be a worrisome condition, able to significantly impact health costs. It is also likely that by counteracting NAFLD, the onset of the cardiovascular disease can be delayed or reduced. The only proven therapeutic strategy for the treatment of fatty liver in overweight and obese children consists of stable lifestyle changes. So far, the prescription of medications, including insulin sensitizers and antioxidants, did not provide better results than lifestyle changes in terms of both biochemical parameters and liver histology. Other medications (i.e., orlistat or lipidlowering drugs) or medical and surgical procedures (i.e., the Roux-en-Y gastric bypass [RYGB]) may be prescribed in the presence of poor compliance to the prescription of lifestyle changes or severe metabolic abnormalities associated with overweight and obesity.
|Title of host publication||Global Perspectives on Childhood Obesity|
|Number of pages||10|
|Publication status||Published - 2011|
ASJC Scopus subject areas
- Health Professions(all)